Herantis Pharma Oyj
Innovative treatments for a better life
Herantis Pharma Plc is a clinical-stage biotechnology company developing treatments for Parkinson's disease. Herantis' lead product HER-096 is a small synthetic peptidomimetic compound derived from the active site of the CDNF protein, combining the unique mechanism of action of the CDNF protein with the potential for subcutaneous delivery. The main objective of the ongoing Phase 1b clinical trial is to demonstrate that repeated subcutaneous doses of HER-096 are safe and well tolerated in patients with Parkinson's disease. In the Phase 1a clinical trial, HER-096 administered subcutaneously was found to be safe, well tolerated and to effectively cross the blood-brain barrier in healthy volunteers.
Herantis shares are listed on the Nasdaq First North Growth Market Finland.
